PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Acetylcysteine - Reduction of sputum viscosity

PAD Profile : Acetylcysteine - Reduction of sputum viscosity

Keywords :
excessive mucous production, mucolytics, COPD, Bronchiectasis
Brand Names Include :
NACSYS, A-CYS, AceCil, Acepiro

Traffic Light Status

Status 1 of 2.

Status :
Green (see narrative)
Important
Formulations :
  • Effervescent tablets
Important Information :
Prescribe generically as 600mg effervescent tablets sugar free. Do not use in patients with bronchospasm or history of asthma. Do not use in fluid or sodium restricted patients.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :
Type
Document
Review Date

Status 2 of 2.

Status :
Non Formulary
Important
Formulations :
  • Capsules
  • Granules
  • Oral solution
  • Powder
  • Tablets
Important Information :
These are either unlicensed or are not considered cost-effective treatment options - see guidelines for recommended products.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
U
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
03 April 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Area Prescribing Committee approved the Primary Care guidance for prescribing oral mucolytics.

Acetylcysteine should be prescribed generically.

Refer to the guidance for full details.

Associated BNF Codes

03. Respiratory System
03.07.00. Mucolytics
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More